<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02067468</url>
  </required_header>
  <id_info>
    <org_study_id>111545921657</org_study_id>
    <nct_id>NCT02067468</nct_id>
  </id_info>
  <brief_title>Optimal Strategy for the Management of ASCUS Cytology in Health Care Services of Medellin, Colombia</brief_title>
  <acronym>ASCUS-COL</acronym>
  <official_title>Evaluation of Strategies for Optimal Clinical Management of Women With Atypical Squamous Cells of Undetermined Significance (ASC-US)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Universidad de Antioquia</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>International Agency for Research on Cancer</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Barts and the London School of Medicine and Dentistry</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Instituto Colombiano para el Desarrollo de la Ciencia y la Tecnología (COLCIENCIAS)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>QIAGEN Gaithersburg, Inc</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>EPS SURA</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>EPS COMFAMA</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>EPS COMFENALCO</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>DINAMICA IPS</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Laboratorio Clínico Escuela de Microbiología (Universidad de Antioquia)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Metrosalud</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Universidad de Antioquia</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Cervical cancer as well cervical preneoplastic abnormalities (CIN2+) are cause by human
      papillomavirus (HPV) infection. These abnormalities have been historically detected by
      cervical cytology, but recent evidence shows that HPV testing is superior to cytology to
      detect cervical lesions that eventually will progress to cancer. Despite evidence,
      conventional cytology (Pap) remains as a primary screening test in Colombia and HPV test is
      recommended as a triage test for women with atypical squamous cells of undetermined
      significance (ASC-US) in settings around the world. Women with ASC-US have low risk to CIN2+
      but higher than healthy population, and therefore it is important to provide appropriate
      clinical management. However, there is no consensus of how to deal women with ASC-US and
      therefore there are still three strategies for this purpose: 1) immediate colposcopy, 2)
      repeat conventional cytology at 6 and 12 months and 3) HPV testing. The main objective of
      this study is to compare the effectiveness and the efficient among the strategies as well as
      to evaluate the acceptability of the HPV testing in a real-life setting.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The aim of this study is to compare the effectiveness and efficiency of immediate colposcopy
      (IC), repeat conventional cytology at 6 and 12 months (RC) and HPV triage (HPV) (QIAGEN-The
      digene HPV Test®) for the clinical management of women with ASC-US insured in healthcare
      management organizations (HMO) within the Colombian health security system. This study
      randomized 2,661 20-69 years old women with ASC-US, insured in HMOs in Medellin-Colombia to 3
      arms: IC, RC and HPV. All women are scheduled for a visit at 2 years after recruitment that
      includes HPV-test/cytology and colposcopy either if HPV+ (RLU&gt;=1) or abnormal cytology
      (&gt;=ASC-US). This colposcopy is performed by a trained colposcopist and women are followed-up
      according to a well-defined algorithm. The fewer high-grade cervical neoplasia (CIN2+) rate
      at the end of following will determine the most effective arm. The most efficiency arm will
      be which reach the major effective with the minimum resource (cytologies, colposcopies and
      histologies) consumed. The resource consumed is being retrieved from the HMOs. This study
      also pretends to evaluate the acceptability of the HPV testing. This study will allow us to
      know if within the Colombian health security system, the HPV test will remain superior to
      repeating cytology and/or to inmediate colposcopy as it has been demonstrated in randomized
      controlled trials carried out in outside settings.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2011</start_date>
  <completion_date type="Actual">April 2016</completion_date>
  <primary_completion_date type="Actual">April 2016</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Health Services Research</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Cervical Intraepithelial Neoplasia Grade 2 or higher(CIN2+)</measure>
    <time_frame>2 years after enrollment</time_frame>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">3000</enrollment>
  <condition>Cervical Abnormalities</condition>
  <condition>Cervical Intraepithelial Neoplasia Grade 2/3</condition>
  <condition>Cervical Cancer</condition>
  <arm_group>
    <arm_group_label>HPV test</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Women with ASC-US cytology are HPV tested and those HPV positive are refer to Colposcopy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>COLPOSCOPY</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Women with ASC-US cytology are immediately refer to colposcopy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>CYTOLOGY</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Women with ASC-US Cytology are follow-up with cytology at 6 and/or 12 months and be referred to colposcopy if any of these cytologies is ASC-US or higher</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>HPV test</intervention_name>
    <description>QIAGEN - The Digene HPV test®</description>
    <arm_group_label>HPV test</arm_group_label>
    <other_name>Human Papillomavirus test</other_name>
    <other_name>DNA HPV test</other_name>
    <other_name>High risk HPV test</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>COLPOSCOPY</intervention_name>
    <description>Colposcopy routine health services</description>
    <arm_group_label>HPV test</arm_group_label>
    <arm_group_label>COLPOSCOPY</arm_group_label>
    <arm_group_label>CYTOLOGY</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>cytology</intervention_name>
    <description>Cytology routine health services</description>
    <arm_group_label>CYTOLOGY</arm_group_label>
    <other_name>Pap smear</other_name>
    <other_name>Papanicolaou test</other_name>
    <other_name>cervical cytology</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  ASC-US cytology, living in metropolitan area of Medellin

        Exclusion Criteria:

          -  Previous abnormal cytology
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>69 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gloria I Sanchez, MSc, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Universidad de Antioquia</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Armando Baena, MSc</last_name>
    <role>Study Chair</role>
    <affiliation>Universidad de Antioquia</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Maria C Agudelo, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Universidad de Antioquia</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Alejandra Botero, MSc</last_name>
    <role>Study Chair</role>
    <affiliation>Universidad de Antioquia</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Victor Florez, MSc</last_name>
    <role>Study Chair</role>
    <affiliation>Universidad de Antioquia</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Calatina Villa, BSc</last_name>
    <role>Study Chair</role>
    <affiliation>Universidad de Antioquia</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Astrid Bedoya, MSc</last_name>
    <role>Study Chair</role>
    <affiliation>Universidad de Antioquia</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Guadalupe Posada, MD, Esp</last_name>
    <role>Study Chair</role>
    <affiliation>DINAMICA IPS</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Carlos A Buitrago, MD, Esp</last_name>
    <role>Study Chair</role>
    <affiliation>EPS COMFENALCO</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Juan C Ochoa, MD, Esp</last_name>
    <role>Study Chair</role>
    <affiliation>EPS COMFAMA</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Luis J Gomez, MD, Esp</last_name>
    <role>Study Chair</role>
    <affiliation>DINAMICA IPS</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Tatiana Ramirez, BSc</last_name>
    <role>Study Chair</role>
    <affiliation>Universidad de Antioquia</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Maribel Almonte, MSc, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>International Agency for Research on Cancer (IARC)</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Rolando Herrero, MSc, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>International Agency for Research on Cancer (IARC)</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Peter Sasieni, MSc, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Centre for Cancer Prevention, Queen Mary University of London</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Yessid Álvarez, Student</last_name>
    <role>Study Chair</role>
    <affiliation>Universidad de Antioquia</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Universidad de Antioquia</name>
      <address>
        <city>Medellin</city>
        <state>Antioquia</state>
        <country>Colombia</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Colombia</country>
  </location_countries>
  <reference>
    <citation>Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer. 2010 Dec 15;127(12):2893-917. doi: 10.1002/ijc.25516.</citation>
    <PMID>21351269</PMID>
  </reference>
  <reference>
    <citation>Walboomers JM, Jacobs MV, Manos MM, Bosch FX, Kummer JA, Shah KV, Snijders PJ, Peto J, Meijer CJ, Muñoz N. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol. 1999 Sep;189(1):12-9.</citation>
    <PMID>10451482</PMID>
  </reference>
  <reference>
    <citation>ASCUS-LSIL Traige Study (ALTS) Group. Results of a randomized trial on the management of cytology interpretations of atypical squamous cells of undetermined significance. Am J Obstet Gynecol. 2003 Jun;188(6):1383-92.</citation>
    <PMID>12824967</PMID>
  </reference>
  <reference>
    <citation>Andrés-Gamboa O, Chicaíza L, García-Molina M, Díaz J, González M, Murillo R, Ballesteros M, Sánchez R. Cost-effectiveness of conventional cytology and HPV DNA testing for cervical cancer screening in Colombia. Salud Publica Mex. 2008 Jul-Aug;50(4):276-85.</citation>
    <PMID>18670718</PMID>
  </reference>
  <reference>
    <citation>Schiffman M, Adrianza ME. ASCUS-LSIL Triage Study. Design, methods and characteristics of trial participants. Acta Cytol. 2000 Sep-Oct;44(5):726-42.</citation>
    <PMID>11015972</PMID>
  </reference>
  <reference>
    <citation>Schiffman M, Solomon D. Findings to date from the ASCUS-LSIL Triage Study (ALTS). Arch Pathol Lab Med. 2003 Aug;127(8):946-9. Review.</citation>
    <PMID>12873166</PMID>
  </reference>
  <reference>
    <citation>Arbyn M, Sasieni P, Meijer CJ, Clavel C, Koliopoulos G, Dillner J. Chapter 9: Clinical applications of HPV testing: a summary of meta-analyses. Vaccine. 2006 Aug 31;24 Suppl 3:S3/78-89. Review.</citation>
    <PMID>16950021</PMID>
  </reference>
  <reference>
    <citation>Carozzi FM, Confortini M, Cecchini S, Bisanzi S, Cariaggi MP, Pontenani G, Raspollini MR, Sani C, Zappa M, Ciatto S. Triage with human papillomavirus testing of women with cytologic abnormalities prompting referral for colposcopy assessment. Cancer. 2005 Feb 25;105(1):2-7.</citation>
    <PMID>15593261</PMID>
  </reference>
  <reference>
    <citation>Legood R, Gray A, Wolstenholme J, Moss S. Lifetime effects, costs, and cost effectiveness of testing for human papillomavirus to manage low grade cytological abnormalities: results of the NHS pilot studies. BMJ. 2006 Jan 14;332(7533):79-85. Epub 2006 Jan 6.</citation>
    <PMID>16399769</PMID>
  </reference>
  <reference>
    <citation>Kulasingam SL, Kim JJ, Lawrence WF, Mandelblatt JS, Myers ER, Schiffman M, Solomon D, Goldie SJ; ALTS Group. Cost-effectiveness analysis based on the atypical squamous cells of undetermined significance/low-grade squamous intraepithelial lesion Triage Study (ALTS). J Natl Cancer Inst. 2006 Jan 18;98(2):92-100.</citation>
    <PMID>16418511</PMID>
  </reference>
  <reference>
    <citation>Sheriff SK, Petry KU, Ikenberg H, Crouse G, Mazonson PD, Santas CC. An economic analysis of human papillomavirus triage for the management of women with atypical and abnormal Pap smear results in Germany. Eur J Health Econ. 2007 Jun;8(2):153-60. Epub 2007 Feb 17.</citation>
    <PMID>17308921</PMID>
  </reference>
  <reference>
    <citation>Vanni T, Legood R, Franco EL, Villa LL, Luz PM, Schwartsmann G. Economic evaluation of strategies for managing women with equivocal cytological results in Brazil. Int J Cancer. 2011 Aug 1;129(3):671-9. doi: 10.1002/ijc.25708. Epub 2010 Nov 12.</citation>
    <PMID>20886598</PMID>
  </reference>
  <reference>
    <citation>Dillner L, Kemetli L, Elfgren K, Bogdanovic G, Andersson P, Carlsten-Thor A, Andersson S, Persson E, Rylander E, Grillner L, Dillner J, Törnberg S. Randomized healthservices study of human papillomavirus-based management of low-grade cytological abnormalities. Int J Cancer. 2011 Jul 1;129(1):151-9. doi: 10.1002/ijc.25649. Epub 2010 Nov 9.</citation>
    <PMID>20824706</PMID>
  </reference>
  <reference>
    <citation>Ostensson E, Fröberg M, Hjerpe A, Zethraeus N, Andersson S. Economic analysis of human papillomavirus triage, repeat cytology, and immediate colposcopy in management of women with minor cytological abnormalities in Sweden. Acta Obstet Gynecol Scand. 2010 Oct;89(10):1316-25. doi: 10.3109/00016349.2010.512066. Erratum in: Acta Obstet Gynecol Scand. 2010 Nov;89(11):1497.</citation>
    <PMID>20846064</PMID>
  </reference>
  <reference>
    <citation>Inter-American-Development-Bank. Structured Pluralism: Toward an Innovative Model for the Reform of Health Systems in Latin America. Office of the Chief Economist. 1997;Working Paper 353.</citation>
  </reference>
  <reference>
    <citation>Luce BR, Kramer JM, Goodman SN, Connor JT, Tunis S, Whicher D, Schwartz JS. Rethinking randomized clinical trials for comparative effectiveness research: the need for transformational change. Ann Intern Med. 2009 Aug 4;151(3):206-9. Epub 2009 Jun 30.</citation>
    <PMID>19567619</PMID>
  </reference>
  <reference>
    <citation>Verdoodt F, Szarewski A, Halfon P, Cuschieri K, Arbyn M. Triage of women with minor abnormal cervical cytology: meta-analysis of the accuracy of an assay targeting messenger ribonucleic acid of 5 high-risk human papillomavirus types. Cancer Cytopathol. 2013 Dec;121(12):675-87. doi: 10.1002/cncy.21325. Epub 2013 Jul 23. Review.</citation>
    <PMID>23881840</PMID>
  </reference>
  <reference>
    <citation>Arbyn M, Ronco G, Anttila A, Meijer CJ, Poljak M, Ogilvie G, Koliopoulos G, Naucler P, Sankaranarayanan R, Peto J. Evidence regarding human papillomavirus testing in secondary prevention of cervical cancer. Vaccine. 2012 Nov 20;30 Suppl 5:F88-99. doi: 10.1016/j.vaccine.2012.06.095. Review. Erratum in: Vaccine. 2013 Dec 16;31(52):6266.</citation>
    <PMID>23199969</PMID>
  </reference>
  <reference>
    <citation>Sørbye SW, Arbyn M, Fismen S, Gutteberg TJ, Mortensen ES. Triage of women with low-grade cervical lesions--HPV mRNA testing versus repeat cytology. PLoS One. 2011;6(8):e24083. doi: 10.1371/journal.pone.0024083. Epub 2011 Aug 30.</citation>
    <PMID>21918682</PMID>
  </reference>
  <reference>
    <citation>Arbyn M, Martin-Hirsch P, Buntinx F, Van Ranst M, Paraskevaidis E, Dillner J. Triage of women with equivocal or low-grade cervical cytology results: a meta-analysis of the HPV test positivity rate. J Cell Mol Med. 2009 Apr;13(4):648-59. doi: 10.1111/j.1582-4934.2008.00631.x. Epub 2009 Jan 23.</citation>
    <PMID>19166485</PMID>
  </reference>
  <reference>
    <citation>Cuzick J, Arbyn M, Sankaranarayanan R, Tsu V, Ronco G, Mayrand MH, Dillner J, Meijer CJ. Overview of human papillomavirus-based and other novel options for cervical cancer screening in developed and developing countries. Vaccine. 2008 Aug 19;26 Suppl 10:K29-41. doi: 10.1016/j.vaccine.2008.06.019. Review.</citation>
    <PMID>18847555</PMID>
  </reference>
  <reference>
    <citation>Dalla Palma P, Pojer A, Girlando S. HPV triage of women with atypical squamous cells of undetermined significance: a 3-year experience in an Italian organized programme. Cytopathology. 2005 Feb;16(1):22-6.</citation>
    <PMID>15859311</PMID>
  </reference>
  <reference>
    <citation>Instituto Nacional de C. Recomendaciones para el tratamiento de las pacientes con citologia reportada con células escamosas atipicas de significado indeterminado (ASC-US) en Colombia. Guias de practica clinica (No. 2). Bogota, Colombia: INC, 2007</citation>
  </reference>
  <verification_date>June 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 18, 2014</study_first_submitted>
  <study_first_submitted_qc>February 18, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 20, 2014</study_first_posted>
  <last_update_submitted>June 3, 2016</last_update_submitted>
  <last_update_submitted_qc>June 3, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 6, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Universidad de Antioquia</investigator_affiliation>
    <investigator_full_name>Gloria I. Sanchez, MSc, PhD</investigator_full_name>
    <investigator_title>Associate Professor</investigator_title>
  </responsible_party>
  <keyword>Human Papillomavirus</keyword>
  <keyword>cervical cancer</keyword>
  <keyword>health services research</keyword>
  <keyword>Colombia</keyword>
  <keyword>Cervical Intraepithelial Neoplasia</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Uterine Cervical Neoplasms</mesh_term>
    <mesh_term>Neoplasms</mesh_term>
    <mesh_term>Carcinoma in Situ</mesh_term>
    <mesh_term>Cervical Intraepithelial Neoplasia</mesh_term>
    <mesh_term>Uterine Cervical Dysplasia</mesh_term>
    <mesh_term>Atypical Squamous Cells of the Cervix</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

